Vitamin a derivative paired with Low-Dose radiation shows promise for rare skin cancer

NCT ID NCT05296304

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety of combining bexarotene (a vitamin A-like drug) with ultra-low dose total skin electron beam radiotherapy for people with mycosis fungoides, a common form of cutaneous T-cell lymphoma. About 20 adults with stage IB or higher disease will receive both treatments at the same time. The goal is to see if this combination is safe and possibly more effective than either treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
RECRUITING

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.